Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24752327 | 1.00 | CHRM2 (0.38) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL17294429 | 1.00 | CHRM2 (0.38) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL24792569 | 1.00 | CHRM2 (0.38) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL2627321 | 0.84 | CHRM2 (0.40) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL22475427 | 0.84 | CHRM2 (0.40) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL25666112 | 0.84 | CHRM2 (0.40) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL20419315 | 0.84 | CHRM2 (0.40) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL23982861 | 0.84 | CHRM2 (0.40) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL7912588 | 0.84 | CHRM2 (0.40) | CHRM2CHRM1CYP2D6MEN1KMT2A | |
| SCHEMBL24752585 | 0.84 | CHRM2 (0.38) | CHRM2CHRM1CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | Glaxosmithline Intellectual Property Development Limited (GB) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190681-A1 | 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | CHRM2 3706/4885CHRM1 3744/4885CYP2D6 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.